ArticleInternational journal of molecular sciences2021
Decorin-An Antagonist of TGF-β in Astrocytes of the Optic Nerve.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Emerging roles of granzymes in neurodegeneration and neuroinflammation: mechanistic insights and therapeutic opportunities.Acta neuropathologica · 2026Review
- Article
- TGFβ-mediated dural progenitor cell migration into the coronal suture is crucial for preventing craniosynostosis.Nature communications · 2026Article
- Review
- Decorin Is a Newly Discovered Target of Akkermansia muciniphila in the Treatment of Sepsis-Associated Encephalopathy.CNS neuroscience & therapeutics · 2025Article
- Article
- Decorin: matrix-based pan-cancer tumor suppressor.Molecular and cellular biochemistry · 2025Review
- LRIG1 controls proliferation of adult neural stem cells by facilitating TGFβ and BMP signalling pathways.Communications biology · 2024Article
- Progranulin inhibits autophagy to facilitate intracellular colonization ofFrontiers in cellular and infection microbiology · 2024Article
- Global impact of proteoglycan science on human diseases.iScience · 2023Review
- Small leucine rich proteoglycans: Biology, function and their therapeutic potential in the ocular surface.The ocular surface · 2023Review
- Decorin: a potential therapeutic candidate for ligamentum flavum hypertrophy by antagonizing TGF-β1.Experimental & molecular medicine · 2023Article
- Role of Decorin in the Lens and Ocular Diseases.Cells · 2022Review
- Towards an Understanding of Retinal Diseases and Novel Treatment.International journal of molecular sciences · 2022Article
- Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways.American journal of physiology. Cell physiology · 2022Review
- The Role of Decorin Proteoglycan in Mitophagy.Cancers · 2022Review
- CCN2/CTGF-A Modulator of the Optic Nerve Head Astrocyte.Frontiers in cell and developmental biology · 2022Article
- The Preventive Effect of Decorin on Epidural Fibrosis and Epidural Adhesions After Laminectomy.Frontiers in pharmacology · 2021Article
- Inactivation of BACE2 stimulates release of endothelin-1 from human brain microvascular endothelial cells.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
During the pathogenesis of glaucoma, optic nerve (ON) axons become continuously damaged at the optic nerve head (ONH). This often is associated with reactive astrocytes and increased transforming growth factor (TGF-β) 2 levels. In this study we tested the hypothesis if the presence or absence of decorin (DCN), a small leucine-rich proteoglycan and a natural inhibitor of several members of the TGF family, would affect the expression of the TGF-βs and connective tissue growth factor (CTGF/CCN2) in human ONH astrocytes and murine ON astrocytes. We found that DCN is present in the mouse ON and is expressed by human ONH and murine ON astrocytes. DCN expression and synthesis was significantly reduced after 24 h treatment with 3 nM CTGF/CCN2, while treatment with 4 pM TGF-β2 only reduced expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.